Accounts Receivable, after Allowance for Credit Loss, Current of Kymera Therapeutics, Inc. from 31 Dec 2022 to 30 Jun 2025

Taxonomy & unit: us-gaap: USD
Description: Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary: Kymera Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2022 to 30 Jun 2025.
Kymera Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Jun 2025 was $40,000,000.
Source SEC data: View on sec.gov

Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Kymera Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2025	$40,000,000	+$40,000,000		30 Jun 2025	10-Q	11 Aug 2025	2025	Q2
Q4 2024	$0	-$15,000,000	-100%	31 Dec 2024	10-Q	11 Aug 2025	2025	Q2
Q3 2024	$0			30 Sep 2024	10-Q	31 Oct 2024	2024	Q3
Q2 2024	$0			30 Jun 2024	10-Q	07 Aug 2024	2024	Q2
Q1 2024	$0			31 Mar 2024	10-Q	02 May 2024	2024	Q1
Q4 2023	$15,000,000	+$15,000,000		31 Dec 2023	10-K	27 Feb 2025	2024	FY
Q4 2022	$0			31 Dec 2022	10-K	22 Feb 2024	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.